A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
Status:
Active, not recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of a combination of an investigational WT1
vaccine and another drug called nivolumab. This is the first time that the WT1 vaccine and
nivolumab are being used in combination. Also, to test the safety of a combination of an
investigational NY-ESO-1 vaccine and another drug called nivolumab.